Fiche publication
Date publication
novembre 2016
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PAPATHANASSIOU Dimitri
,
Dr PREVOST Alain
Tous les auteurs :
Dejust S, Morland D, Fabre G, Prevost A, Papathanassiou D
Lien Pubmed
Résumé
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of F-FDG PET/CT for monitoring the effectiveness of this new treatment.
Mots clés
Antineoplastic Agents, administration & dosage, Carcinoma, Non-Small-Cell Lung, diagnostic imaging, Fluorodeoxyglucose F18, Humans, Lung Neoplasms, diagnostic imaging, Neoplasm Metastasis, Positron Emission Tomography Computed Tomography, Protein Kinase Inhibitors, administration & dosage, Pyrimidines, administration & dosage, Radiopharmaceuticals, Receptor Protein-Tyrosine Kinases, genetics, Sulfones, administration & dosage
Référence
Clin Nucl Med. 2016 Nov;41(11):879-880
